Study of BLZ-100 in Pediatric Subjects With CNS Tumors
NCT02462629
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
29
Enrollment
INDUSTRY
Sponsor class
Conditions
Central Nervous System Tumors
Interventions
DRUG:
BLZ-100
Sponsor
Blaze Bioscience Inc.